INS and type 1 diabetes mellitus: Since the introduction of the first insulin pump into clinical practice which allowed continuous subcutaneous insulin infusion (CSII) in the 1970s, the scientific community and T1D patients’ goal for years has been the creation of an artificial pancreatic system (APS) [1,2,3].